Thrombolysis in Myocardial Infarction (TIMI)

Summary

In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).

Conditions

• Cardiovascular Diseases
• Coronary Disease
• Heart Diseases
• Myocardial Infarction
• Myocardial Ischemia

Interventions

DRUG

tissue plasminogen activator

PROCEDURE

angioplasty, transluminal, percutaneous coronary

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  lead NIH

Principal Investigators

• Joseph Babb · Bridgeport Hospital

• Jeffery Borer · Weill Medical College of Cornell University

• Bernard Chaitman · St. Louis University Medical Center

• James Chesebro · Mayo Foundation

• Richard Davison · Northwestern University

• Harold Dodge · University of Washington

• Frederick Feit · NYU Langone Health

• Charles Francis · Yale University

• Joel Gore · University of Massachusetts, Worcester

• Michael Herman · New York Medical College

• Morrison Hodges · University of Minnesota

• Harvey Kemp · St. Luke's-Roosevelt Institute for Health Sciences

• Genell Knatterud · Maryland Medical Research Institute

• Costas Lambrew · MaineHealth

• Philip Ludbrook · Washington University School of Medicine

• Kenneth Mann · University of Vermont

• John Markis · Beth Israel Hospital

• John Morrison · North Shore University Hospital

• Hiltrud Mueller · Montefiore Medical Center

• Eric Powers · Columbia University

• Robert Roberts · Baylor College of Medicine

• Williams Rogers · University of Alabama at Birmingham

• Allan Ross · George Washington University

• Thomas Ryan · University Hospital Inc.

• Marc Schweiger · Baystate Medical Center

• Gerald Timmis · William Beaumont Hospitals

• James Willerson · University of Texas

• David Williams · Rhode Island Hospital

• Barry Zaret · Yale University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1983-04-30

Completion

1990-12-31